{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:11:51Z","timestamp":1781493111651,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["VIR\/18\/2018\/ECD-I"],"award-info":[{"award-number":["VIR\/18\/2018\/ECD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jceh.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:38:27Z","timestamp":1679629107000},"page":"736-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-9381","authenticated-orcid":false,"given":"Amit","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita","family":"Katiyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mayank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Rungta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhai","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Deep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asari","family":"Sana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveer","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-494X","authenticated-orcid":false,"given":"Rakesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2023.03.007_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/bmb\/ldv004","article-title":"Revolution in hepatitis C antiviral therapy","volume":"113","author":"Sadler","year":"2015","journal-title":"Br Med Bull"},{"key":"10.1016\/j.jceh.2023.03.007_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2023.03.007_bib3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib4","series-title":"Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection","year":"2018"},{"key":"10.1016\/j.jceh.2023.03.007_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jceh.2016.07.001","article-title":"Indian national association for study of the liver (INASL) guidance for antiviral therapy against HCV infection: update 2016","volume":"6","author":"Puri","year":"2016","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12664-017-0763-3","article-title":"Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: an Indian experience","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2023.03.007_bib8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jhep.2019.07.006","article-title":"Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting","volume":"71","author":"Dhiman","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib9","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.13633","article-title":"Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis","volume":"43","author":"Majumdar","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2023.03.007_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/jvh.12989","article-title":"Findings from a large Asian chronic hepatitis C real-life study","volume":"25","author":"Lim","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2023.03.007_bib11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"Review article: HCV genotype 3 - the new treatment challenge","volume":"39","author":"Ampuero","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2023.03.007_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jgh.14466","article-title":"Burden of hepatitis C virus infection in India: a systematic review and meta-analysis","volume":"34","author":"Goel","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jgh.15827","article-title":"Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: a systematic review","volume":"37","author":"Goel","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib14","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jceh.2022.06.003","article-title":"A\u00a0systematic review of risk factors for hepatitis C virus infection among low-risk population in India","volume":"12","author":"Shalimar","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.meegid.2009.04.001","article-title":"Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort","volume":"9","author":"Narahari","year":"2009","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jceh.2023.03.007_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jceh.2022.06.002","article-title":"Liver stiffness is reduced to normal after successful renal transplantation: a prospective cohort study","volume":"12","author":"Bhadauria","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40506-017-0136-6","article-title":"Retreatment options following HCV direct acting antiviral failure","volume":"9","author":"Zuckerman","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.007_bib18","doi-asserted-by":"crossref","first-page":"e3288","DOI":"10.1093\/cid\/ciaa1318","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics","volume":"73","author":"Papaluca","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.007_bib19","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/liv.15075","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis","volume":"41","author":"Patel","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2023.03.007_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients","volume":"26","author":"Belperio","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2023.03.007_bib21","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jceh.2021.06.023","article-title":"Use of sofosbuvir\/velpatasvir\/voxilaprevir for sofosbuvir nonresponder genotype 3 HCV infection in India","volume":"12","author":"Tiwari","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2019.06.022","article-title":"High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world","volume":"71","author":"Perez","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.03.007_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijid.2021.12.320","article-title":"Frequency distribution of\u00a0HCV resistance-associated variants in infected patients treated\u00a0with direct-acting antivirals","volume":"115","author":"Cabral","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jceh.2023.03.007_bib25","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1002\/jmv.26971","article-title":"Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C","volume":"93","author":"Elhence","year":"2021","journal-title":"J\u00a0Med Virol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097368832300052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097368832300052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:10:02Z","timestamp":1760854202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S097368832300052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S097368832300052X"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2023.03.007","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}